Original Articles: PDF OnlyCD4+ Lymphocyte Count in African Patients Co-infected with HIV and TuberculosisMartin, D. J.; Sim, J. G. M.; Sole, G. J.; Rymer, L.; Shalekoff, S.; van Niekerk, A. B. N.; Becker, P.; Weilbach, C. N.; Iwanik, J.; Keddy, K.; Miller, G. B.; Ozbay, B.; Ryan, A.; Viscovic, T.; Woolf, M. Author Information MRC AIDS Virus Research Unit, National Institute for Virology and University of Witwatersrand, MRC Biostatics Unit, University of Witwatersrand, and Rietfontein Hospital, Sandringham, South Africa Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology: April 1995 - Volume 8 - Issue 4 - p 386-391 Free Abstract The objectives of this study were (a) to compare the CD4+ lymphocyte profiles over time of two groups of patients hospitalized for tuberculosis (TB) treatment [a group of patients with TB only (TB group) and a group dually infected by HIV and TB (HIV/TB group)] and (b) to assess the usefulness of the total lymphocyte count (TLC) as a surrogate of the CD4+ lymphocyte count in the HIV/TB group. A total of 345 patients were enrolled in the study of whom 104 (29.8%) were HIV seropositive (HIV/TB). On admission, the CD4+ lymphocyte counts of the HIV/TB cohort were significantly lower than the TB group with medians of 230 (interquartile range, 90–475) and 630 (500–865), respectively (p <0.0001). The CD4+ lymphocyte count increased significantly in both cohorts on routine TB treatment. A TLC of 1,300–1,500 cells/mm3 was found to be predictive of a CD4+ lymphocyte count of <200 cells/mm3 both on admission and after 1 month of TB therapy. We conclude from this study that the positive influence of TB therapy on the CD4+ lymphocyte count strongly suggests an additional avenue of influence on the course of HIV infection, whereas the usefulness of the TLC as a surrogate estimation of CD4+ lymphocyte count in HIV/TB patients has important implications for the developing world. © Lippincott-Raven Publishers.